Litcius/Paper detail

Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial

Shukui Qin, Zhenggang Ren, Zhiqiang Meng, Zhendong Chen, Xiaoli Chai, Jianping Xiong, Yuxian Bai, Lin Yang, Hong Zhu, Weijia Fang, Xiaoyan Lin, Xiaoming Chen, Enxiao Li, Linna Wang, Chunxia Chen, Jianjun Zou

2020The Lancet Oncology639 citationsDOI

Topics & Concepts

MedicineHepatocellular carcinomaInternal medicineClinical endpointRandomized controlled trialAdverse effectSorafenibClinical trialIntention-to-treat analysisSurgeryGastroenterologyHepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and BiomarkersCholangiocarcinoma and Gallbladder Cancer Studies
Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial | Litcius